PT  - JOURNAL ARTICLE
AU  - Maria A. Kokosi
AU  - George A. Margaritopoulos
AU  - Athol U. Wells
TI  - Personalised medicine in interstitial lung diseases
AID  - 10.1183/16000617.0117-2017
DP  - 2018 Jun 30
TA  - European Respiratory Review
PG  - 170117
VI  - 27
IP  - 148
4099  - http://err.ersjournals.com/content/27/148/170117.short
4100  - http://err.ersjournals.com/content/27/148/170117.full
SO  - EUROPEAN RESPIRATORY REVIEW2018 Jun 30; 27
AB  - Interstitial lung diseases in general, and idiopathic pulmonary fibrosis in particular, are complex disorders with multiple pathogenetic pathways, various disease behaviour profiles and different responses to treatment, all facets that make personalised medicine a highly attractive concept. Personalised medicine is aimed at describing distinct disease subsets taking into account individual lifestyle, environmental exposures, genetic profiles and molecular pathways. The cornerstone of personalised medicine is the identification of biomarkers that can be used to inform diagnosis, prognosis and treatment stratification. At present, no data exist validating a personalised approach in individual diseases. However, the importance of the goal amply justifies the characterisation of genotype and pathway signatures with a view to refining prognostic evaluation and trial design, with the ultimate aim of selecting treatments according to profiles in individual patients.Personalised medicine provides a potential road map for guiding clinical care in interstitial lung diseases http://ow.ly/xZop30iQOoQ